Phase III Trial meets Primary Endpoint for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Patients with severe asthma with an eosinophilic phenotype who are 12 years of age or older may now receive treatment with FASENRA as an add-on maintenance treatment. Note that…